Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook

Dermapharm Holding SE

11/08/2026 06:43

Corrects to "EBITDA margin", from "adjusted EBITDA margin", in table

Overview
Germany branded pharmaceuticals maker's preliminary H1 2026 revenue grew 2.9% yr/yr
Adjusted EBITDA for preliminary H1 2026 rose 
Company confirmed full-year 2026 guidance for revenue and adjusted EBITDA

Outlook
Dermapharm confirms 2026 revenue guidance of EUR 1,182–1,218 mln
Company maintains 2026 adjusted EBITDA outlook at EUR 331–341 mln
Dermapharm anticipates positive trend across all segments in H2 2026

Result Drivers
BRANDED PHARMACEUTICALS - Strong organic growth and first-time contributions from Mucos Group and F. Trenka supported results
OTHER HEALTHCARE PRODUCTS - Segment revenue declined moderately due to weaker purchasing power, but earnings benefited from favorable exchange rates and improved material costs
PARALLEL IMPORTS - Revenue declined as expected from portfolio realignment, but earnings improved due to focus on higher-margin products

Company press release: ID:nEQ3Bggyca

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
EUR 591 mln
 
H1 Adjusted EBITDA
 
EUR 163.20 mln
 
H1 EBITDA
 
EUR 184.50 mln
 
H1 EBITDA Margin
 
31.20%
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Dermapharm Holding SE is €48.00, about 18.5% above its August 10 closing price of €40.50
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 18 three months ago

Reuters Recommended Reads
Aug 10 - Canada's Medexus Q1 revenue beats on GRAFAPEX strength
Aug 10 - India's Gland Pharma beats quarterly profit view on strong Europe, US sales
Aug 9 - RadNet raises outlook as Q2 revenue jumps 25%, adjusted EPS beats estimates 

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)